USP33 Regulates DNA Damage Response and Carcinogenesis Through Deubiquitylating and Stabilising p53

Abstract

The de-ubiquitinase USP33 has been shown to possess either tumour-promoting or inhibitory effect on human cancer cells. However, all these findings are mainly based on in vitro cell culture models, and the in vivo evidence, which is more plausible to digest the functional role of USP33 in carcinogenic process, is still lacking. Here, we demonstrate that USP33 modulates DNA damage responses including cell cycle arrest and apoptosis induction through associating with p53. It directly interacts with p53 to mediate its de-ubiquitination and further stabilisation under DNA damage condition. Depletion of USP33 induces an enhanced level of p53 ubiquitination, which de-stabilises p53 protein leading to impaired DNA damage responses. Furthermore, USP33 silencing shows either promoted or inhibited effect on cell proliferation in human cancer cells with p53 WT and mutant background, respectively. Consistently, mice with hepatocyte-specific USP33 knockout are more sensitive to nitrosodiethylamine (DEN)-induced hepatocarcinogenesis compared to wild type mice. Thus, our in vitro and in vivo evidences illustrate that USP33 possesses anti-tumour activity via regulating p53 stability and activity.

References

[1] K. Niu, H. Fang, Z. Chen, et al., “USP33 Deubiquitinates PRKN/Parkin and Antagonizes its Role in Mitophagy,” Autophagy 16, no. 4 (2020): 724-734.

[2] A. Zhang, Z. Huang, W. Tao, et al., “USP33 Deubiquitinates and Stabilizes HIF-2alpha to Promote Hypoxia Response in Glioma Stem Cells,” EMBO Journal 41, no. 7 (2022): e109187.

[3] J. Chen, W. Shan, Q. Jia, et al., “USP33 Facilitates the Ovarian Cancer Progression via Deubiquitinating and Stabilizing CBX2,” Oncogene 43 (2024): 3170-3183.

[4] P. Wen, R. Kong, J. Liu, et al., “USP33, a New Player in Lung Cancer, Mediates Slit-Robo Signaling,” Protein & Cell 5, no. 9 (2014): 704-713.

[5] M. Fischer and M. A. Sammons, “Determinants of p53 DNA Binding, Gene Regulation, and Cell Fate Decisions,” Cell Death and Differentiation 31, no. 7 (2024): 836-843.

[6] A. B. Williams and B. Schumacher, “p53 in the DNA-Damage-Repair Process,” Cold Spring Harbor Perspectives in Medicine 6, no. 5 (2016): a026070.

[7] F. Guo, C. Zhang, F. Wang, et al., “Deubiquitinating Enzyme USP33 Restrains Docetaxel-Induced Apoptosis via Stabilising the Phosphatase DUSP1 in Prostate Cancer,” Cell Death and Differentiation 27, no. 6 (2020): 1938-1951.

[8] Q. Gan, J. Shao, Y. Cao, et al., “USP33 Regulates c-Met Expression by Deubiquitinating SP1 to Facilitate Metastasis in Hepatocellular Carcinoma,” Life Sciences 261 (2020): 118316.

[9] Y. Liu, Z. Su, O. Tavana, and W. Gu, “Understanding the Complexity of p53 in a New Era of Tumor Suppression,” Cancer Cell 42, no. 6 (2024): 946-967.

[10] S. Niazi, M. Purohit, and J. H. Niazi, “Role of p53 Circuitry in Tumorigenesis: A Brief Review,” European Journal of Medicinal Chemistry 158 (2018): 7-24.

[11] M. Pan and C. Blattner, “Regulation of p53 by E3s,” Cancers (Basel) 13, no. 4 (2021): 745.

[12] L. Chen, S. Liu, and Y. Tao, “Regulating Tumor Suppressor Genes: Post-Translational Modifications,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 90.

[13] N. Koo, A. K. Sharma, and S. Narayan, “Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death,” International Journal of Molecular Sciences 23, no. 9 (2022): 5005.

[14] C. C. Chao, “Mechanisms of p53 Degradation,” Clinica Chimica Acta 438 (2015): 139-147.

[15] J. Wang, W. Liu, L. Zhang, and J. Zhang, “Targeting Mutant p53 Stabilization for Cancer Therapy,” Frontiers in Pharmacology 14 (2023): 1215995.

[16] S. K. Kwon, M. Saindane, and K. H. Baek, “p53 Stability is Regulated by Diverse Deubiquitinating Enzymes,” Biochimica Et Biophysica Acta. Reviews on Cancer 1868, no. 2 (2017): 404-411.

[17] J. Yuan, K. Luo, L. Zhang, J. C. Cheville, and Z. Lou, “USP10 Regulates p53 Localization and Stability by Deubiquitinating p53,” Cell 140, no. 3 (2010): 384-396.

[18] X. X. Sun, K. B. Challagundla, and M. S. Dai, “Positive Regulation of p53 Stability and Activity by the Deubiquitinating Enzyme Otubain 1,” EMBO Journal 31, no. 3 (2012): 576-592.

[19] M. Akutsu, I. Dikic, and A. Bremm, “Ubiquitin Chain Diversity at a Glance,” Journal of Cell Science 129, no. 5 (2016): 875-880.

[20] A. Hafner, M. L. Bulyk, A. Jambhekar, and G. Lahav, “The Multiple Mechanisms That Regulate p53 Activity and Cell Fate,” Nature Reviews. Molecular Cell Biology 20, no. 4 (2019): 199-210.

[21] K. Yang, Y. Xiao, L. Zhong, et al., “p53-Regulated lncRNAs in Cancers: From Proliferation and Metastasis to Therapy,” Cancer Gene Therapy 30, no. 11 (2023): 1456-1470.

[22] H. Wang, P. Liao, S. X. Zeng, and H. Lu, “It Takes a Team: A Gain-of-Function Story of p53-R249S,” Journal of Molecular Cell Biology 11, no. 4 (2019): 277-283.

[23] P. Liao, S. X. Zeng, X. Zhou, et al., “Mutant p53 Gains its Function via c-Myc Activation Upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding,” Molecular Cell 68, no. 6 (2017): 1134-1146.e1136.

[24] F. Li, P. Huangyang, M. Burrows, et al., “FBP1 Loss Disrupts Liver Metabolism and Promotes Tumorigenesis Through a Hepatic Stellate Cell Senescence Secretome,” Nature Cell Biology 22, no. 6 (2020): 728-739.

[25] C. M. Eischen, “Genome Stability Requires p53,” Cold Spring Harbor Perspectives in Medicine 6, no. 6 (2016): a026096.

[26] B. J. Aubrey, G. L. Kelly, A. Janic, M. J. Herold, and A. Strasser, “How Does p53 Induce Apoptosis and How Does This Relate to p53-Mediated Tumour Suppression?,” Cell Death and Differentiation 25, no. 1 (2018): 104-113.

[27] K. Engeland, “Cell Cycle Regulation: p53-p21-RB Signaling,” Cell Death and Differentiation 29, no. 5 (2022): 946-960.

[28] J. Liu, C. Zhang, W. Hu, and Z. Feng, “Tumor Suppressor p53 and Metabolism,” Journal of Molecular Cell Biology 11, no. 4 (2019): 284-292.

[29] A. Maillet and S. Pervaiz, “Redox Regulation of p53, Redox Effectors Regulated by p53: A Subtle Balance,” Antioxidants & Redox Signaling 16, no. 11 (2012): 1285-1294.

[30] D. Ghatak, D. Das Ghosh, and S. Roychoudhury, “Cancer Stemness: p53 at the Wheel,” Frontiers in Oncology 10 (2020): 604124.

[31] Q. Cheng, L. Chen, Z. Li, W. S. Lane, and J. Chen, “ATM Activates p53 by Regulating MDM2 Oligomerization and E3 Processivity,” EMBO Journal 28, no. 24 (2009): 3857-3867.

[32] J. Liu, L. Cao, Y. Wang, et al., “The Phosphorylation-Deubiquitination Positive Feedback Loop of the CHK2-USP7 Axis Stabilizes p53 Under Oxidative Stress,” Cell Reports 43, no. 6 (2024): 114366.

[33] M. R. Braghini, O. Lo Re, I. Romito, et al., “Epigenetic Remodelling in Human Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 107.

[34] Y. Boege, M. Malehmir, M. E. Healy, et al., “A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development,” Cancer Cell 32, no. 3 (2017): 342-359.e310.

[35] X. Wu, J. Gu, Y. Patt, et al., “Mutagen Sensitivity as a Susceptibility Marker for Human Hepatocellular Carcinoma,” Cancer Epidemiology, Biomarkers & Prevention 7, no. 7 (1998): 567-570.

[36] J. H. Hung, C. F. Teng, H. C. Hung, et al., “Genomic Instabilities in Hepatocellular Carcinoma: Biomarkers and Application in Immunotherapies,” Annals of Hepatology 29, no. 6 (2024): 101546.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.